scholarly journals Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients

Hepatology ◽  
2019 ◽  
Author(s):  
Kiran V.K. Koelfat ◽  
Mark P. Plummer ◽  
Frank G. Schaap ◽  
Martin Lenicek ◽  
Peter L.M. Jansen ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Fibroblast Growth ◽  
Gallbladder Dyskinesia ◽  
Fibroblast Growth Factor 19

scholarly journals Fibroblast growth factor 23, endothelium biomarkers and acute kidney injury in critically-ill patients

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Fernanda Macedo de Oliveira Neves ◽  
Camila Barbosa Araújo ◽  
Daniele Ferreira de Freitas ◽  
Bianca Fernandes Távora Arruda ◽  
Leonardo José Monteiro de Macêdo Filho ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Fibroblast Growth Factor 23 ◽  
Kidney Injury ◽  
Fibroblast Growth

Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis

2018 ◽  
Vol 24 (5) ◽  
pp. 595-605 ◽  
Author(s):  
Astrid Ruiz-Margáin ◽  
Alessandra Pohlmann ◽  
Patrick Ryan ◽  
Robert Schierwagen ◽  
Luis A. Chi-Cervera ◽  
...  
Keyword(s):  
Growth Factor ◽  
Liver Failure ◽  
Fibroblast Growth Factor ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Chronic Liver ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Chronic Liver Failure ◽  
Early Predictor

scholarly journals Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients

2018 ◽  
Vol 13 (4) ◽  
pp. 531-541 ◽  
Author(s):  
David E. Leaf ◽  
Edward D. Siew ◽  
Michele F. Eisenga ◽  
Karandeep Singh ◽  
Finnian R. Mc Causland ◽  
...  
Keyword(s):  
Vitamin D ◽  
Growth Factor ◽  
Confidence Interval ◽  
Fibroblast Growth Factor ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Mineral Metabolism ◽  
Fibroblast Growth Factor 23 ◽  
Vitamin D Metabolites ◽  
Fibroblast Growth

Background and objectives Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D–regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI.Design, setting, participants, & measurementsWe measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (n=1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality.ResultsIn the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death.ConclusionsHigher FGF23 levels are independently associated with greater mortality in critically ill patients.

Sign in / Sign up

Export Citation Format

Share Document